Baader Helvea downgraded Newron Pharma to Add from Buy with a price target of CHF 7.20, up from CHF 2.60. The analyst updated the model to account for evenamide’s recent success in the open-label trial in treatment-resistant schizophrenia. It cites valuation for the downgrade.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly